Fused Ring Compound Multi-Target Antidepressant Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant drugs have limitations such as slow onset of action, low efficacy in a significant percentage of patients, and side effects, necessitating the development of new compounds with improved therapeutic effects for depression and related central nervous system diseases.
Innovation Solution
A fused ring compound represented by formula (I) and its stereoisomers or pharmaceutically acceptable salts, which are synthesized through various methods, exhibit high affinity to 5-HT3 receptors and multi-targeting action on monoamine transporters, offering rapid and effective treatment for central nervous system diseases with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antidepressant drugs (SSRIs, SNRIs) are used, then they can improve monoamine neurotransmission, but they have slow onset of action and low efficacy in 30-40% of patients
Solution Approach 1:
The fused ring compound is designed to simultaneously target multiple receptors including 5-HT3, 5-HT1A, and 5-HT2A receptors, as well as monoamine transporters. This multi-target approach allows the single compound to address multiple pathological mechanisms of depression concurrently, improving both efficacy and onset speed by engaging diverse neural pathways rather than relying on a single mechanism like conventional SSRIs or SNRIs
Solution Approach 2:
The compound employs a composite molecular structure combining a fused ring core (formula I) with various substituent groups (R1, G ring, X, m, n, p, q parameters) that confer multiple pharmacological activities. This structural composite enables the molecule to interact with multiple receptor types and transporters, achieving enhanced therapeutic effects and faster onset compared to single-mechanism antidepressants
2Reliability
If higher doses of antidepressant drugs are used to improve efficacy, then therapeutic effect may increase, but side effects increase
Solution Approach 1:
The compound exhibits selective affinity for specific receptor subtypes (5-HT3, 5-HT1A, 5-HT2A) and monoamine transporters, with preferential binding to therapeutic targets in the central nervous system. This localized selectivity allows effective antidepressant action at lower doses while minimizing off-target effects and side effects that would occur with non-selective high-dose therapy
Solution Approach 2:
The patent optimizes multiple molecular parameters including the fused ring core structure, substituent positions (m, n, p, q), and functional groups (R1, G ring, X) to fine-tune the compound's pharmacological profile. These parameter optimizations enhance binding affinity for therapeutic targets while reducing affinity for receptors associated with side effects, achieving better therapeutic index at lower doses
3Adaptability or versatility
If new antidepressant compounds are developed to overcome limitations of existing drugs, then therapeutic spectrum and efficacy improve, but drug development complexity increases
Solution Approach 1:
The drug development process is segmented into systematic stages: (1) designing the core fused ring structure of formula I, (2) synthesizing compounds with varying substituents (R1, G ring, X, m, n, p, q), (3) screening for multi-target activity, and (4) optimizing pharmacological properties. This segmentation allows complex multi-target antidepressants to be developed through manageable, modular steps rather than attempting to optimize all properties simultaneously
Data Source
AI summary
The present invention relates to a fused ring compound represented by general formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof. The compound provided in the present invention is useful for treating, preventing and/or controlling various nervous system disorders. The compound provided in the present invention modulates one or more monoamine transporters, inhibits the reuptake of endogenous monoamines such as dopamine, 5-hydroxytryptamine, and norepinephrine (e.g., from the synaptic cleft), and/or modulates the 5-HT3 receptor.